Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220026/S019

Symplicity G3 Renal Denervation RF Generator

Medtronic, Inc. · Decision date Oct 23, 2026

MEDTECHLEDGER EXPLANATIONP220026/S019

What did the FDA decide?

The FDA record for P220026/S019 describes a 30-day notice for the Symplicity G3 Renal Denervation RF Generator whose stated purpose is approval for replacement of manufacturing lines and inspection process changes for circuit boards. The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager, or supplier. The notice does not specify which lines were replaced, which inspection steps changed, or what validation supported the change.

The identifier ties this action to the original PMA P220026, but this is a manufacturing supplement, not an approval of the whole device system. The source statement gives a reported purpose, not evidence of safety or clinical effectiveness, and the record describes no change to indications. Details on the circuit boards and inspection criteria remain absent from the supplied fields.

FDA approval order statement

approval for replacement of manufacturing lines and inspection process changes for circuit boards in the Symplicity G3 Renal Denervation RF Generator
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 23, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P220026/S019
Regulatory pathway
PMA supplement
Product code
QYI
Decision code
OK30
Decision date
Oct 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Ablation catheter, renal denervation.

Product code
QYI
FDA device class
3

For the original device and its historical approval scope, see PMA P220026. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220026 · Original PMA

    Symplicity Spyral Renal Denervation System

  2. P220026/S014 · Related supplement

    Symplicity Spyral Renal Denervation System

  3. P220026/S019 received

    Application receipt date recorded by FDA.

  4. P220026/S019 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P220026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220026

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalNov 17, 2023FDA
Medtronic, Inc.PMA supplementSep 10, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3576 Unocal Pl., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records